Mediplantex National Pharmaceutical JSC (HNX:MED)
Vietnam
· Delayed Price · Currency is VND 22,800
0.00 (0.00%)
At close: Aug 7, 2025
HNX:MED Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| Revenue | 360,486 | 443,136 | 402,741 | 401,051 | 343,951 | 521,391 | Upgrade
|
| Revenue Growth (YoY) | -22.34% | 10.03% | 0.42% | 16.60% | -34.03% | -28.43% | Upgrade
|
| Cost of Revenue | 276,434 | 350,574 | 319,663 | 321,750 | 275,877 | 404,519 | Upgrade
|
| Gross Profit | 84,052 | 92,561 | 83,078 | 79,301 | 68,074 | 116,872 | Upgrade
|
| Selling, General & Admin | 66,826 | 70,368 | 68,897 | 70,666 | 59,184 | 89,651 | Upgrade
|
| Operating Expenses | 66,826 | 70,368 | 68,897 | 70,666 | 59,184 | 89,651 | Upgrade
|
| Operating Income | 17,226 | 22,193 | 14,181 | 8,634 | 8,890 | 27,221 | Upgrade
|
| Interest Expense | -1,393 | -3,787 | -5,394 | -5,004 | -3,619 | -5,815 | Upgrade
|
| Interest & Investment Income | 790.11 | 790.11 | 6,580 | 5,811 | 4,790 | 5,419 | Upgrade
|
| Currency Exchange Gain (Loss) | -1,298 | -690.35 | -45.37 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -399.59 | 928.43 | -212.84 | -774.96 | -4,533 | 4,159 | Upgrade
|
| EBT Excluding Unusual Items | 14,925 | 19,434 | 15,109 | 8,666 | 5,528 | 30,984 | Upgrade
|
| Gain (Loss) on Sale of Assets | -16.21 | -16.21 | -185.78 | - | - | - | Upgrade
|
| Pretax Income | 14,909 | 19,418 | 14,923 | 8,666 | 5,528 | 30,984 | Upgrade
|
| Income Tax Expense | 3,237 | 4,171 | 3,179 | 2,300 | 1,781 | 6,562 | Upgrade
|
| Net Income | 11,673 | 15,247 | 11,744 | 6,366 | 3,747 | 24,422 | Upgrade
|
| Net Income to Common | 11,673 | 15,247 | 11,744 | 6,366 | 3,747 | 24,422 | Upgrade
|
| Net Income Growth | -28.15% | 29.83% | 84.49% | 69.88% | -84.66% | -31.97% | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 12 | 9 | 6 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 12 | 9 | 6 | 6 | Upgrade
|
| Shares Change (YoY) | -5.83% | - | 32.18% | 49.59% | -0.05% | -0.01% | Upgrade
|
| EPS (Basic) | 940.68 | 1228.59 | 946.32 | 678.00 | 597.00 | 3889.00 | Upgrade
|
| EPS (Diluted) | 940.68 | 1228.59 | 946.32 | 678.00 | 597.00 | 3889.00 | Upgrade
|
| EPS Growth | -23.70% | 29.83% | 39.58% | 13.57% | -84.65% | -31.96% | Upgrade
|
| Free Cash Flow | - | 37,674 | -84,502 | -91,039 | 7,746 | 60,527 | Upgrade
|
| Free Cash Flow Per Share | - | 3035.74 | -6809.19 | -9696.32 | 1234.13 | 9638.35 | Upgrade
|
| Dividend Per Share | - | - | 900.000 | 500.000 | 250.000 | - | Upgrade
|
| Dividend Growth | - | - | 80.00% | 100.00% | - | - | Upgrade
|
| Gross Margin | 23.32% | 20.89% | 20.63% | 19.77% | 19.79% | 22.41% | Upgrade
|
| Operating Margin | 4.78% | 5.01% | 3.52% | 2.15% | 2.58% | 5.22% | Upgrade
|
| Profit Margin | 3.24% | 3.44% | 2.92% | 1.59% | 1.09% | 4.68% | Upgrade
|
| Free Cash Flow Margin | - | 8.50% | -20.98% | -22.70% | 2.25% | 11.61% | Upgrade
|
| EBITDA | 24,924 | 30,109 | 22,625 | 18,654 | 18,426 | 37,241 | Upgrade
|
| EBITDA Margin | 6.91% | 6.79% | 5.62% | 4.65% | 5.36% | 7.14% | Upgrade
|
| D&A For EBITDA | 7,699 | 7,916 | 8,444 | 10,020 | 9,536 | 10,020 | Upgrade
|
| EBIT | 17,226 | 22,193 | 14,181 | 8,634 | 8,890 | 27,221 | Upgrade
|
| EBIT Margin | 4.78% | 5.01% | 3.52% | 2.15% | 2.58% | 5.22% | Upgrade
|
| Effective Tax Rate | 21.71% | 21.48% | 21.30% | 26.55% | 32.22% | 21.18% | Upgrade
|
| Revenue as Reported | 360,486 | 443,136 | 402,741 | 401,051 | 343,951 | 521,391 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.